全文获取类型
收费全文 | 60334篇 |
免费 | 4711篇 |
国内免费 | 2452篇 |
专业分类
耳鼻咽喉 | 425篇 |
儿科学 | 1920篇 |
妇产科学 | 497篇 |
基础医学 | 8437篇 |
口腔科学 | 1464篇 |
临床医学 | 7512篇 |
内科学 | 7704篇 |
皮肤病学 | 462篇 |
神经病学 | 9343篇 |
特种医学 | 3403篇 |
外国民族医学 | 8篇 |
外科学 | 5910篇 |
综合类 | 8383篇 |
现状与发展 | 15篇 |
一般理论 | 2篇 |
预防医学 | 1326篇 |
眼科学 | 874篇 |
药学 | 4007篇 |
14篇 | |
中国医学 | 1200篇 |
肿瘤学 | 4591篇 |
出版年
2023年 | 658篇 |
2022年 | 1009篇 |
2021年 | 1685篇 |
2020年 | 1792篇 |
2019年 | 1629篇 |
2018年 | 1837篇 |
2017年 | 2044篇 |
2016年 | 2266篇 |
2015年 | 2407篇 |
2014年 | 4405篇 |
2013年 | 5065篇 |
2012年 | 3804篇 |
2011年 | 4493篇 |
2010年 | 3843篇 |
2009年 | 3574篇 |
2008年 | 3524篇 |
2007年 | 3476篇 |
2006年 | 3149篇 |
2005年 | 2753篇 |
2004年 | 2131篇 |
2003年 | 1718篇 |
2002年 | 1227篇 |
2001年 | 1091篇 |
2000年 | 870篇 |
1999年 | 692篇 |
1998年 | 589篇 |
1997年 | 579篇 |
1996年 | 477篇 |
1995年 | 474篇 |
1994年 | 423篇 |
1993年 | 301篇 |
1992年 | 320篇 |
1991年 | 271篇 |
1990年 | 256篇 |
1989年 | 189篇 |
1988年 | 185篇 |
1987年 | 210篇 |
1986年 | 175篇 |
1985年 | 215篇 |
1984年 | 194篇 |
1983年 | 127篇 |
1982年 | 173篇 |
1981年 | 146篇 |
1980年 | 163篇 |
1979年 | 144篇 |
1978年 | 108篇 |
1977年 | 124篇 |
1976年 | 112篇 |
1975年 | 82篇 |
1973年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
71.
72.
73.
目的多中心临床应用对比分析8排及16排移动CT的成像质量及性能特点、检查耗时、人工成本及辐射剂量值等。
方法解放军总医院第七医学中心神经外科自2010年8月至2020年7月应用8排移动CT行头部扫描90 059例次,解放军总医院第七医学中心神经外科联合多家医院自2017年3月至2020年7月应用16排移动CT行头部扫描10 969例次,分别采集患者头部扫描成像、检查时间、人工成本(人员累计耗时),以及辐射剂量值:CT剂量指数(CTDIvol)、剂量长度乘积(DLP)、有效剂量(ED)。另外随机选择同期60例次64排大型CT检测值作为对比。
结果(1)成像分析:8排移动CT头部扫描90 059例次,其中急诊室82 843例次(91.99%)、ICU 7090例次(7.87%)、手术室126例次(0.14%)。16排移动CT头部扫描10 959例次,其中急诊室8601例次(78.41%)、ICU 879例次(8.01%)、手术室31例次(0.28%)、车/船/机载头部扫描1458例次(13.29%)。2组成像质量基本相同,与8排移动CT组相比较,16排移动CT安装有精密导轨控制扫描和减振器,扫描速度快,运动伪影少,具有平扫+增强、脑血管造影(CTA)和脑灌注成像(CTP)等多种成像功能。(2)扫描时间与辐射剂量:16排、8排移动CT及64排大型CT的扫描时间、人工成本、辐射剂量(CTDIvol、DLP、ED)比较,差异均有统计学意义(P<0.05)。
结论16排移动CT成像质量优良,扫描速度快耗时少、人工成本低、辐射剂量低,具有平扫、增强及CTA、CTP多种成像功能。 相似文献
74.
75.
《The Journal of arthroplasty》2020,35(2):485-489
BackgroundTo reduce costs of orthopedic implants, the government decided to standardize implants used across different specialties in a group of hospitals located in the same geographic area. The usual cemented stem used in the context of intracapsular displaced geriatric hip fractures was replaced by another stem. Abnormal intraoperative calcar and trochanteric fractures were noted. The purpose of this study is to determine the incidence of intraoperative periprosthetic fractures following an intracapsular displaced hip fracture treated with this specific cemented stem compared to the previous implant.MethodsThis is a retrospective cohort study comparing an historic cohort of hip fractures treated with the OmniFit EON (Stryker, Kalamazoo, MI) cemented stem with a new cohort of patients who received the Corail (DePuy Synthes, Warsaw, IN) cemented stem. Four orthopedic surgeons reviewed operative reports and postoperative radiographs.ResultsThe treatment group included 348 patients who received the Corail stem. The control group included 77 patients. The 2 groups had similar baseline characteristics (P > .05) except for the presence of dementia. Incidence of intraoperative calcar or greater trochanteric fracture was 15.5% for the Corail group and 2.7% for the control group (P < .05). No patient-related factors or surgeon-related factors were related to a higher number of fractures in the treatment group (P > .05).ConclusionThe Corail cemented stem presents an abnormal number of iatrogenic intraoperative fractures following displaced femoral neck fracture in our geriatric population. No external factor seems to explain this high number of fractures. Implant design should be questioned.Level of EvidenceIII. 相似文献
76.
77.
《Journal of Pharmaceutical Analysis》2022,12(4):601-609
A sensitive and rapid liquid chromatography tandem mass spectrometry (LC-MS/MS) method was established for the quantification of total and unbound concentrations of LY3214996, an extracellular signal-regulated kinase inhibitor; abemaciclib, a cyclin-dependent kinase 4/6 inhibitor; and abemaciclib active metabolites, M2 and M20, in human plasma, brain tumor, and cerebrospinal fluid samples. The method was validated over a concentration range of 0.2–500 nM within a total run time of 3.8 min using isocratic elution on a Kinetex™ F5 column. Detection was performed on a Sciex QTRAP 6500+ mass spectrometer employing multiple reaction monitoring mode under positive electrospray ionization. The intra- and inter-batch accuracy as well as the precision of the method for all matrices was within ±20% and ≤20% at the lower limit of quantification, and within ±15% and ≤15% for other quality control levels for all analytes. The unbound fractions of drugs and metabolites in spiked and patient samples were determined using an optimized equilibrium dialysis. The validated method was successfully applied in a phase 0/2 clinical trial to assess the central nervous system penetration of LY3214996 and abemaciclib. 相似文献
78.
79.
80.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献